CD151蛋白在子宫内膜腺癌组织中的表达及临床意义

发布时间：2018-04-21 10:43

本文选题：子宫内膜腺癌 + 免疫组织化学　；参考：《川北医学院》2015年硕士论文

【摘要】：目的:通过检测跨膜蛋白CD151在60例子宫内膜腺癌和42例正常子宫内膜组织中的表达水平,以及CD151在不同分期、不同分化程度的癌组织的表达差异,探讨其临床意义。方法:采用免疫组化S-P法检测CD151在60例子宫内膜腺癌以及42例正常子宫内膜组织的表达水平,通过双评半定量法进行评分,积分≥2分为阳性,2分为阴性。采用单因素方差分析、卡方检验,分析CD151在子宫内膜腺癌组织与正常子宫内膜组织,癌症组织不同分期、不同分化程度、不同年龄组间表达水平的差异性。结果:CD151在60例子宫内膜腺癌的阳性表达率为71.7%(43/60),42例正常子宫内膜组织表达率为35.7%(15/42),两组间比较P=0.0001,差异有统计学意义;不同临床病理分期的子宫内膜癌组织中CD151阳性表达如下:I期为39.1%(9/23),II期为66.7%(14/21),Ⅲ期为81.3%(13/16),两两间比较P=0.023,差异有统计学意义;CD151在子宫内膜癌不同组织分化程度中阳性表达如下:G1:40.9%(9/22),G2:58.8%(10/17),G3:81.0%(17/21),两两间比较P=0.027,差异有统计学意义;不同年龄组内膜腺癌组织表达情况:≥50岁组为75.0%(39/52),50岁组为62.5%(5/8),组间比较P=0.429,差异无统计学意义。结论:通过数据分析显示CD151在子宫内膜腺癌较正常子宫内膜组织表达明显上调,提示CD151可能参与子宫内膜癌的发生,据此推测其可能对子宫内膜癌的分子生物水平机制研究具有重要意义;通过对CD151在不同临床病理分期、不同组织分化程度的癌组织中的表达水平分析,发现CD151的表达水平可能作为一个判断子宫内膜腺癌患者预后的分子指标、指导临床选择治疗措施。
[Abstract]:Objective: To investigate the expression of transmembrane protein CD151 in 60 cases of endometrial adenocarcinoma and 42 normal endometrium, and the difference in the expression of CD151 in different stages and differentiation, and to explore its clinical significance. Methods: the immunohistochemical S-P method was used to detect the CD151 in 60 cases of endometrial adenocarcinoma and 42 normal uterus. The expression level of intima tissue was scored by a double rating semi quantitative method. The scores were more than 2 points positive and 2 were negative. Single factor analysis of variance and chi square test were used to analyze the difference of CD151 in endometrial adenocarcinoma tissue and normal endometrium, different stages of cancer tissue, different degree of differentiation, and the difference of expression level between different age groups. Results: the positive expression rate of CD151 in 60 cases of endometrial adenocarcinoma was 71.7% (43/60), the expression rate of normal endometrium in 42 cases was 35.7% (15/42), and the difference was statistically significant between the two groups. The positive forms of CD151 in endometrial carcinoma tissues of different clinical and pathological stages were as follows: I phase was 39.1% (9/23), II period 66.7% (14/21), and stage III of 81. were 81.. 3% (13/16), 22 compared with P=0.023, the difference was statistically significant. The positive expression of CD151 in the differentiation degree of endometrial carcinoma was as follows: G1:40.9% (9/22), G2:58.8% (10/17), G3:81.0% (17/21), 22 comparison P=0.027, the difference was statistically significant; the expression of endometrial adenocarcinoma in different age groups was 75% (39/52) in 50 years old group (39/52), 50 The age group was 62.5% (5/8), and the difference was not statistically significant between the groups. Conclusion: data analysis showed that the expression of CD151 in endometrial adenocarcinoma was significantly up-regulated than normal endometrium, suggesting that CD151 might be involved in the occurrence of endometrial carcinoma, so it might be possible to study the molecular biological level mechanism of endometrial carcinoma. By analyzing the expression level of CD151 in different clinical pathological stages and differentiation of different tissues, it is found that the expression level of CD151 may be a molecular marker to judge the prognosis of endometrial adenocarcinoma and guide the clinical selection.

【学位授予单位】：川北医学院
【学位级别】：硕士
【学位授予年份】：2015
【分类号】：R737.33

【参考文献】